Appointment of Dr Darren Patti to Group Chief Operating Officer
ASX,
Telix is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March...
Read moreLatest News
Category: ASX
ASX,
Telix is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March...
Read moreASX,
Telix today announces a general meeting of shareholders to be held at The Wesley Conference Centre, Lyceum Room, 220 Pitt Street, Sydney, NSW 2000 and online via https://meetings.linkgroup.com/TLXGM24 on Friday...
Read moreTelix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure...
Read moreTelix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics...
Read moreTelix today announces its financial results for the financial year ended 31 December 2023....
Read moreTelix today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.)...
Read moreTelix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February...
Read moreTelix today advises it is presenting at the 42nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San...
Read moreTelix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging...
Read moreTelix Group Chief Medical Officer, Dr Colin Hayward, moderated an expert discussion with global key opinion leaders on the evolving treatment landscape for PSMA-targeted radiopharmaceuticals, including Telix’s first-in-class investigational radio-antibody...
Read more